ENTITY
Sciclone Pharmaceuticals

Sciclone Pharmaceuticals (6600 HK)

77
Analysis
Health CareChina
SciClone Pharmaceuticals (Holdings) Limited operates as a biopharmaceutical company. The Company develops produces and sells oncology drug, infectious diseases drugs and other products. SciClone Pharmaceuticals (Holdings) markets its products throughout China.
more
Refresh
02 Apr 2024 13:38

Sciclone Pharmaceuticals (6600.HK) - The Privatization Offers a Good Exit Opportunity

The success rate of privatization could be 70-80%. The time could be about six months. The annualized rate of return isn't attractive.It's up to...

Logo
341 Views
Share
01 Apr 2024 07:00

SciClone Pharma (6600 HK): Privatisation At IPO Price

This looks like a clean deal. The Offer is not contingent on specific regulatory approvals. Assuming late July payment, I'd pay up to ~$18/share.

Logo
511 Views
Share
01 Apr 2024 00:31

Merger Arb Mondays (01 Apr) - SciClone, IntelliCentrics, CIMC Vehicles, Lawson, Roland DG, MMA

This week, the highest gross spreads are SciClone (17.2%), Qantm IP (15.0%), Genex Power (12.2%), Southern Cross (11.2%), China TCM (7.5%), QV...

Logo
382 Views
Share
28 Mar 2024 22:13

SciClone Pharma (6600 HK): GL Capital’s Scheme Offer at HK$18.80

The offer price has been declared final. It is reasonable, aligning with the all-time high and the IPO price. This is a done deal.

Logo
675 Views
Share
19 Mar 2024 17:27

SciClone Pharma (6600 HK): Privatisation Déjà Vu All over Again?

A GL Capital-led consortium will likely once again lead the privatisation. An offer price at or slightly above the IPO price (HK$18.80) would be...

Logo
281 Views
Share
x